Alnylam to Showcase RNAi Therapeutics at ESC Congress 2025 with New Data on Hypertension and ATTR Amyloidosis Programs

Alnylam Pharmaceuticals will present new data on RNAi therapeutics at the ESC Congress 2025, highlighting the transformative potential of RNAi in cardiovascular disease treatment. The KARDIA-3 Phase 2 study on zilebesiran for hypertension and the HELIOS-B Phase 3 study on AMVUTTRA for ATTR amyloidosis with cardiomyopathy will be showcased. The data could bolster investor confidence and drive future revenue growth, but investors should remain cautious about regulatory hurdles and market competition.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading company in the field of RNA interference (RNAi) therapeutics, is set to present new data on its innovative therapies at the upcoming European Society of Cardiology (ESC) Congress 2025. The presentations will focus on the transformative potential of RNAi therapeutics in the treatment of cardiovascular diseases, including hypertension and transthyretin amyloidosis (ATTR) with cardiomyopathy.

Key highlights of the presentations include data from the KARDIA-3 Phase 2 study evaluating the investigational RNAi therapeutic, zilebesiran, in patients with uncontrolled hypertension and high cardiovascular risk. The study will be presented as a late-breaking abstract in the Hot Line 4 session on August 30, 2025. Additionally, data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic that delivers rapid knockdown of transthyretin, will be showcased. The presentation will include results from the 12-month follow-up period of the ongoing open-label extension (OLE) of HELIOS-B, providing further insights into the sustained longer-term benefits of treatment with AMVUTTRA. An analysis examining the effect of AMVUTTRA on days lost to death and/or hospitalization (DLDH) will also be presented [1].

The presentations are significant as they highlight the potential of RNAi therapeutics to revolutionize the treatment of cardiovascular diseases, which remain a global health crisis and a leading cause of death worldwide. According to the World Health Organization, cardiovascular diseases account for approximately 20 million deaths annually [2]. The data presented at the ESC Congress could bolster investor confidence and drive future revenue growth for Alnylam, given the unmet need for innovative therapies in these areas.

However, investors should remain cautious about potential regulatory hurdles and market competition. The safety and efficacy of zilebesiran, for instance, have not been established or evaluated by the FDA, EMA, or any other health authority. Additionally, the market for cardiovascular disease treatments is highly competitive, with established players and numerous new entrants vying for market share. Alnylam will need to navigate these challenges to successfully commercialize its RNAi therapeutics.

In conclusion, Alnylam Pharmaceuticals' presentations at the ESC Congress 2025 are set to shed light on the transformative potential of RNAi therapeutics in cardiovascular disease treatment. While the data could drive investor confidence and future revenue growth, investors should remain vigilant about regulatory challenges and market competition.

References:
[1] https://www.businesswire.com/news/home/20250811966575/en/Alnylam-to-Present-Progress-in-Transforming-the-Treatment-of-Cardiovascular-Disease-with-RNAi-Therapeutics-at-European-Society-of-Cardiology-Congress-2025
[2] World Health Organization. Cardiovascular diseases. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases (accessed July 02, 2025).